Karyopharm Therapeutics Inc KPTI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KPTI is a good fit for your portfolio.
News
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
-
Karyopharm to Participate at the Jefferies Global Healthcare Conference
-
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
-
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
-
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
-
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
Trading Information
- Previous Close Price
- $0.96
- Day Range
- $0.93–1.00
- 52-Week Range
- $0.62–1.95
- Bid/Ask
- $0.94 / $0.98
- Market Cap
- $120.94 Mil
- Volume/Avg
- 1.7 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.80
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 325
- Website
- https://www.karyopharm.com
Comparables
Valuation
Metric
|
KPTI
|
ALLK
|
SWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.76 | 4.96 |
Price/Sales | 0.80 | — | 94.89 |
Price/Cash Flow | — | — | — |
Price/Earnings
KPTI
ALLK
SWTX
Financial Strength
Metric
|
KPTI
|
ALLK
|
SWTX
|
---|---|---|---|
Quick Ratio | 2.75 | 3.88 | 6.56 |
Current Ratio | 3.04 | 4.11 | 6.85 |
Interest Coverage | −5.52 | — | — |
Quick Ratio
KPTI
ALLK
SWTX
Profitability
Metric
|
KPTI
|
ALLK
|
SWTX
|
---|---|---|---|
Return on Assets (Normalized) | −48.38% | −54.70% | −40.43% |
Return on Equity (Normalized) | — | −73.03% | −46.62% |
Return on Invested Capital (Normalized) | −162.28% | −64.58% | −50.77% |
Return on Assets
KPTI
ALLK
SWTX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Lbhxqfrsz | Jzzq | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Jqhcsdpbp | Xskmff | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Phxvhjgny | Skwbhhs | $118.7 Bil | |||
Moderna Inc
MRNA
| Fmcptlsd | Mmcc | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Vtqgncsh | Wfxbhsl | $29.7 Bil | |||
argenx SE ADR
ARGX
| Kydwqpc | Bzxd | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Wtfdzqc | Byn | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Twthmsp | Plhqq | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Vdrbbcb | Dnbx | $15.0 Bil | |||
Incyte Corp
INCY
| Rhmsdldr | Shkgln | $13.5 Bil |